{"id":"fluindione","rwe":[],"tags":[{"label":"fluindione","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"B01AA12","category":"atc"},{"label":"Active","category":"status"},{"label":"Anticoagulants","category":"pharmacology"},{"label":"Hematologic Agents","category":"pharmacology"}],"phase":"phase_2","safety":{"safetySignals":[{"llr":1365.868,"date":"","count":489,"signal":"International normalised ratio increased","source":"DrugCentral FAERS","actionTaken":"Reported 489 times (LLR=1366)"},{"llr":769.858,"date":"","count":555,"signal":"Drug interaction","source":"DrugCentral FAERS","actionTaken":"Reported 555 times (LLR=770)"},{"llr":740.994,"date":"","count":593,"signal":"Acute kidney injury","source":"DrugCentral FAERS","actionTaken":"Reported 593 times (LLR=741)"},{"llr":401.917,"date":"","count":136,"signal":"Shock haemorrhagic","source":"DrugCentral FAERS","actionTaken":"Reported 136 times (LLR=402)"},{"llr":365.445,"date":"","count":102,"signal":"Cerebral haematoma","source":"DrugCentral FAERS","actionTaken":"Reported 102 times (LLR=365)"},{"llr":348.777,"date":"","count":207,"signal":"Hyperkalaemia","source":"DrugCentral FAERS","actionTaken":"Reported 207 times (LLR=349)"},{"llr":347.604,"date":"","count":163,"signal":"Haematoma","source":"DrugCentral FAERS","actionTaken":"Reported 163 times (LLR=348)"},{"llr":247.992,"date":"","count":133,"signal":"Melaena","source":"DrugCentral FAERS","actionTaken":"Reported 133 times (LLR=248)"},{"llr":225.855,"date":"","count":303,"signal":"Anaemia","source":"DrugCentral FAERS","actionTaken":"Reported 303 times (LLR=226)"},{"llr":201.682,"date":"","count":159,"signal":"Bradycardia","source":"DrugCentral FAERS","actionTaken":"Reported 159 times (LLR=202)"},{"llr":163.761,"date":"","count":82,"signal":"Subdural haematoma","source":"DrugCentral FAERS","actionTaken":"Reported 82 times (LLR=164)"},{"llr":139.918,"date":"","count":83,"signal":"Hepatocellular injury","source":"DrugCentral FAERS","actionTaken":"Reported 83 times (LLR=140)"},{"llr":138.726,"date":"","count":96,"signal":"Lactic acidosis","source":"DrugCentral FAERS","actionTaken":"Reported 96 times (LLR=139)"},{"llr":129.368,"date":"","count":99,"signal":"Rectal haemorrhage","source":"DrugCentral FAERS","actionTaken":"Reported 99 times (LLR=129)"},{"llr":118.422,"date":"","count":142,"signal":"Overdose","source":"DrugCentral FAERS","actionTaken":"Reported 142 times (LLR=118)"}],"commonSideEffects":[{"effect":"Atrial fibrillation","drugRate":"10.1%","placeboRate":"","totalAtRisk":405,"totalAffected":41,"trialsReporting":1},{"effect":"Pyrexia","drugRate":"4.7%","placeboRate":"","totalAtRisk":405,"totalAffected":19,"trialsReporting":1},{"effect":"Atrial flutter","drugRate":"3.7%","placeboRate":"","totalAtRisk":405,"totalAffected":15,"trialsReporting":1},{"effect":"Dyspnea","drugRate":"3.5%","placeboRate":"","totalAtRisk":405,"totalAffected":14,"trialsReporting":1},{"effect":"Palpitations","drugRate":"3.0%","placeboRate":"","totalAtRisk":405,"totalAffected":12,"trialsReporting":1},{"effect":"Nasopharyngitis","drugRate":"2.2%","placeboRate":"","totalAtRisk":405,"totalAffected":9,"trialsReporting":1},{"effect":"Headache","drugRate":"2.0%","placeboRate":"","totalAtRisk":405,"totalAffected":8,"trialsReporting":1},{"effect":"Dizziness","drugRate":"2.0%","placeboRate":"","totalAtRisk":405,"totalAffected":8,"trialsReporting":1},{"effect":"Hypertension","drugRate":"2.0%","placeboRate":"","totalAtRisk":405,"totalAffected":8,"trialsReporting":1},{"effect":"Hypotension","drugRate":"2.0%","placeboRate":"","totalAtRisk":405,"totalAffected":8,"trialsReporting":1},{"effect":"Pericarditis","drugRate":"1.5%","placeboRate":"","totalAtRisk":405,"totalAffected":6,"trialsReporting":1},{"effect":"Nausea","drugRate":"1.5%","placeboRate":"","totalAtRisk":405,"totalAffected":6,"trialsReporting":1},{"effect":"Cough","drugRate":"1.5%","placeboRate":"","totalAtRisk":405,"totalAffected":6,"trialsReporting":1},{"effect":"Back pain","drugRate":"1.5%","placeboRate":"","totalAtRisk":405,"totalAffected":6,"trialsReporting":1},{"effect":"Fatigue","drugRate":"1.2%","placeboRate":"","totalAtRisk":405,"totalAffected":5,"trialsReporting":1},{"effect":"Non-cardiac chest pain","drugRate":"1.2%","placeboRate":"","totalAtRisk":405,"totalAffected":5,"trialsReporting":1},{"effect":"Vomiting","drugRate":"1.2%","placeboRate":"","totalAtRisk":405,"totalAffected":5,"trialsReporting":1},{"effect":"Abdominal pain upper","drugRate":"1.2%","placeboRate":"","totalAtRisk":405,"totalAffected":5,"trialsReporting":1},{"effect":"Alanine aminotransferase increased","drugRate":"1.2%","placeboRate":"","totalAtRisk":405,"totalAffected":5,"trialsReporting":1},{"effect":"Pain in extremity","drugRate":"1.2%","placeboRate":"","totalAtRisk":405,"totalAffected":5,"trialsReporting":1},{"effect":"Cardiac flutter","drugRate":"1.0%","placeboRate":"","totalAtRisk":405,"totalAffected":4,"trialsReporting":1},{"effect":"Bronchitis","drugRate":"1.0%","placeboRate":"","totalAtRisk":405,"totalAffected":4,"trialsReporting":1},{"effect":"Procedural pain","drugRate":"1.0%","placeboRate":"","totalAtRisk":405,"totalAffected":4,"trialsReporting":1},{"effect":"Atrial tachycardia","drugRate":"0.7%","placeboRate":"","totalAtRisk":405,"totalAffected":3,"trialsReporting":1},{"effect":"Diarrhea","drugRate":"0.7%","placeboRate":"","totalAtRisk":405,"totalAffected":3,"trialsReporting":1},{"effect":"Atrioventricular block first degree","drugRate":"0.7%","placeboRate":"","totalAtRisk":405,"totalAffected":3,"trialsReporting":1},{"effect":"Arteriovenous fistula","drugRate":"0.7%","placeboRate":"","totalAtRisk":405,"totalAffected":3,"trialsReporting":1},{"effect":"Post procedural complication","drugRate":"0.7%","placeboRate":"","totalAtRisk":405,"totalAffected":3,"trialsReporting":1},{"effect":"Hypokalemia","drugRate":"0.5%","placeboRate":"","totalAtRisk":405,"totalAffected":2,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"0.5%","placeboRate":"","totalAtRisk":405,"totalAffected":2,"trialsReporting":1},{"effect":"Atrial thrombosis","drugRate":"0.5%","placeboRate":"","totalAtRisk":405,"totalAffected":2,"trialsReporting":1},{"effect":"Flatulence","drugRate":"0.5%","placeboRate":"","totalAtRisk":405,"totalAffected":2,"trialsReporting":1},{"effect":"Arthralgia","drugRate":"0.5%","placeboRate":"","totalAtRisk":405,"totalAffected":2,"trialsReporting":1},{"effect":"Renal impairment","drugRate":"0.5%","placeboRate":"","totalAtRisk":405,"totalAffected":2,"trialsReporting":1},{"effect":"Phrenic nerve paralysis","drugRate":"0.2%","placeboRate":"","totalAtRisk":405,"totalAffected":1,"trialsReporting":1},{"effect":"Liver disorder","drugRate":"0.2%","placeboRate":"","totalAtRisk":405,"totalAffected":1,"trialsReporting":1},{"effect":"Leukocytosis","drugRate":"0.0%","placeboRate":"","totalAtRisk":405,"totalAffected":0,"trialsReporting":1},{"effect":"Hypercholesterolemia","drugRate":"0.0%","placeboRate":"","totalAtRisk":405,"totalAffected":0,"trialsReporting":1},{"effect":"Bradycardia","drugRate":"0.0%","placeboRate":"","totalAtRisk":405,"totalAffected":0,"trialsReporting":1}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"previscan","offLabel":[],"synonyms":["fluindione","previscan"],"timeline":[],"approvals":[],"brandName":"Previscan","ecosystem":[],"mechanism":{"target":"Arachidonate 5-lipoxygenase","modality":"Small Molecule","drugClass":"fluindione","explanation":"Think of it like a brake on your car's engine. Previscan blocks a specific part of the engine that helps make blood clots, which can prevent strokes and heart attacks. By blocking this part, Previscan helps prevent blood clots from forming.","oneSentence":"Previscan works by inhibiting vitamin K-dependent clotting factors in the liver.","technicalDetail":"Previscan exerts its anticoagulant effect by inhibiting the gamma-carboxylation of vitamin K-dependent clotting factors, including prothrombin and factors II, VII, IX, and X, in the liver."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1194","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FLUINDIONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FLUINDIONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:33:17.028462","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T11:16:06.305264+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"dicoumarol","drugSlug":"dicoumarol","fdaApproval":"1944-07-31","relationship":"same-class"},{"drugName":"phenindione","drugSlug":"phenindione","fdaApproval":"","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"warfarin","drugSlug":"warfarin","fdaApproval":"1954-06-08","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"phenprocoumon","drugSlug":"phenprocoumon","fdaApproval":"1957-12-30","patentStatus":"Unknown","relationship":"same-class"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"fluindione","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"dicoumarol","brandName":"dicoumarol","genericName":"dicoumarol","approvalYear":"1944","relationship":"same-class"},{"drugId":"phenindione","brandName":"phenindione","genericName":"phenindione","approvalYear":"","relationship":"same-class"},{"drugId":"warfarin","brandName":"warfarin","genericName":"warfarin","approvalYear":"1954","relationship":"same-class"},{"drugId":"phenprocoumon","brandName":"phenprocoumon","genericName":"phenprocoumon","approvalYear":"1957","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05825573","phase":"PHASE3","title":"Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-05-15","conditions":["Intracardiac Thrombus","STEMI","Heart Failure"],"enrollment":340,"completionDate":"2026-02"},{"nctId":"NCT02800941","phase":"","title":"Bleeding Frequency Under Anticoagulant Treatment in Pulmonary Hypertension","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2017-07-05","conditions":["Pulmonary Arterial Hypertension"],"enrollment":203,"completionDate":"2023-09-05"},{"nctId":"NCT03772366","phase":"","title":"Genital Haemorrhage in Woman of Childbearing Age Treated for Venous Thromboembolism Disease : Comparison According to Oral Anticoagulant and Impact on Quality of Life","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2019-06-01","conditions":["Genital Haemorrhage"],"enrollment":453,"completionDate":"2024-01-31"},{"nctId":"NCT02286414","phase":"","title":"Benefit/Risk in Real Life of New Oral Anticoagulants and Vitamin K Antagonists in Patients Aged 80 Years and Over","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-02","conditions":["Atrial Fibrillation"],"enrollment":159,"completionDate":"2021-11"},{"nctId":"NCT02161965","phase":"PHASE4","title":"Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation","status":"COMPLETED","sponsor":"University Hospital, Angers","startDate":"2013-05-21","conditions":["Permanent Atrial Fibrillation","Venous Thrombosis","Pulmonary Embolism","Anticoagulation Treatment at Least > or = to 12-month"],"enrollment":51,"completionDate":"2018-02-16"},{"nctId":"NCT02942576","phase":"PHASE3","title":"Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2017-03-21","conditions":["Atrial Fibrillation"],"enrollment":632,"completionDate":"2018-09-24"},{"nctId":"NCT02227550","phase":"PHASE4","title":"Apixaban During Atrial Fibrillation Catheter Ablation: Comparison to Vitamin K Antagonist Therapy","status":"COMPLETED","sponsor":"Atrial Fibrillation Network","startDate":"2014-12","conditions":["Atrial Fibrillation"],"enrollment":676,"completionDate":"2017-09"},{"nctId":"NCT02823093","phase":"","title":"Aortic Calcification and Vitamin K Antagonists","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2016-04","conditions":["Vascular Calcification"],"enrollment":338,"completionDate":"2017-04"},{"nctId":"NCT01349530","phase":"NA","title":"Evaluating of CREATIF an Anti-coagulation Clinic","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-05","conditions":["Vitamin K Antagonist"],"enrollment":110,"completionDate":"2014-01"},{"nctId":"NCT02814955","phase":"","title":"Electrophysiological Effects of NACOS and AVK on Pulmonary Veins and Left Atrium in Paroxysmal AF Catheter Ablation","status":"UNKNOWN","sponsor":"University Hospital, Caen","startDate":"2015-06","conditions":["Atrial Fibrillation"],"enrollment":90,"completionDate":"2017-09"},{"nctId":"NCT01674647","phase":"PHASE3","title":"Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-10","conditions":["Atrial Fibrillation"],"enrollment":1504,"completionDate":"2014-01"},{"nctId":"NCT00313469","phase":"","title":"Sources of the Variability of the Response to Fluindione in Elderly Patients (PREPA)","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-09","conditions":["Cardiovascular Disease"],"enrollment":152,"completionDate":"2008-04"},{"nctId":"NCT00966290","phase":"PHASE4","title":"Anticoagulant Clinics and Vitamin K Antagonists","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2003-02","conditions":["Blood Coagulation Disorders"],"enrollment":1006,"completionDate":"2006-12"},{"nctId":"NCT00925197","phase":"PHASE3","title":"Patient International Normalised Ratio (INR) Self-Testing Program","status":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2004-05","conditions":["Mechanical Aortic and/or Mitral Valve Replacement Operation"],"enrollment":206,"completionDate":"2009-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"005420","UNII":"EQ35YMS20Q","CHEBI":"CHEBI:134975","INN_ID":"4519","RXNORM":"50097","UMLSCUI":"C0117899","ChEMBL_ID":"CHEMBL24924","KEGG_DRUG":"D07969","DRUGBANK_ID":"DB13136","PUBCHEM_CID":"68942","SNOMEDCT_US":"19351000122101","MESH_SUPPLEMENTAL_RECORD_UI":"C017673"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":150,"therapeuticAreas":["Gastroenterology"],"atcClassification":{"source":"DrugCentral","atcCode":"B01AA12","allCodes":["B01AA12"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Previscan (FLUINDIONE) is a small molecule drug in the fluindione class, but specific details about its target and mechanism of action are not available. It is not clear if it is FDA-approved or off-patent. The approved indications for Previscan are not specified. As a result, its commercial status, half-life, bioavailability, and generic manufacturers are also unknown. Further research is needed to understand the safety considerations and clinical use of Previscan.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":3,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T11:16:06.305264+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":true,"score":3}}